CoChat

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

Open access
Weyer, Christian, Gottlieb, Alan, Kim, Dennis D., Lutz, Karen, Schwartz, Sherwyn, Gutierrez, Maria, Wang, Yan, Ruggles, James A., Kolterman, Orville G., Maggs, David G. · 2003 · Diabetes Care
Cited by 107

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

OBJECTIVE—To assess the postprandial glucose-lowering effect of the human amylin analog pramlintide when given with either regular insulin or insulin lispro in subjects with type 1 diabetes, with an emphasis on the optimal dose timing relative to meals. RESEARCH DESIGN AND METHODS—In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 1 diabetes using regular insulin and 21 subjects with type 1 diabetes using insulin lispro underwent five consecutive mixed meal tests. In randomized order, subjects received subcutaneous injections of placebo at −15 min or 60 μg pramlintide at −15, 0, +15, or +30 min relative to the meal after an overnight fast. Regular insulin or insulin lispro was injected at −30 and 0 min, respectively, at doses that were adjusted appropriately for both the content of the standardized meal and the anticipated effects of pramlintide. Plasma glucose concentrations were measured before and during the 4-h postmeal period. RESULTS—In both the regular insulin and insulin lispro groups, pramlintide injections at all four time points lowered the postprandial glucose excursion (36 to >100% reduction in incremental area under the concentration time curve from 0 to 4 h (AUC0–4 h) compared with placebo. However, only preprandial injections of pramlintide (−15 and 0 min) were able to prevent the initial postprandial surge in glucose. The optimal time for pramlintide injection was 0 min, which reduced the postprandial glucose excursion by >100% compared with regular insulin plus placebo (incremental AUC0–4 h: −0.6 ± 2.5 vs. 11.0 ± 2.9 mmol · h−1 · l−1, P < 0.0007) and by 75% compared with insulin lispro plus placebo (incremental AUC0–4 h: 2.5 ± 2.1 vs. 10.0 ± 2.5 mmol · h−1 · l−1, P < 0.0098). No serious adverse events were reported. CONCLUSIONS—Pramlintide, given at or just before a meal, reduces the postprandial glucose excursion in subjects with type 1 diabetes, regardless of whether added to regular insulin or a rapid-acting insulin analog.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diacare.26.11.3074

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 107

Metadata

Authors
Weyer, C., Gottlieb, A., Kim, D. D., Lutz, K., Schwartz, S., Gutierrez, M., Wang, Y., Ruggles, J. A., Kolterman, O. G., & Maggs, D. G.
Venue
Diabetes Care
Published
2003-11-01
Volume
26
Issue
11
Pages
3074-3079
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2061027504
Cited by
107
References
9
FWCI
4.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/diacare.26.11.3074
The paper
Weyer, C., Gottlieb, A., Kim, D. D., Lutz, K., Schwartz, S., Gutierrez, M., Wang, Y., Ruggles, J. A., Kolterman, O. G., & Maggs, D. G. (2003). Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/diacare.26.11.3074

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.